NC-LENOVO
10.11.2021 15:02:09 CET | Business Wire | Press release
Lenovo™ today announced that DreamWorks Animation has selected Lenovo as its preferred workstation innovation partner to deliver the high-end power and performance needed to bring its next cutting-edge animation feature films to life. This PC collaboration further strengthens the companies’ partnership, as it expands upon the technology leader’s current role as DreamWorks’ data center innovation partner. As part of this multi-year agreement, DreamWorks will deploy Lenovo workstations, including the ThinkStation P620 and ThinkStation P920 , across all departments for the development of content and characters, including the highly anticipated release of the studio’s upcoming film, “The Bad Guys.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005429/en/
The extension of this partnership follows the rollout of a new on-premises Lenovo computing infrastructure designed to transform DreamWorks’ data center into a high-performance, ultra-scalable and sustainable operations center for all of its content creation.
With consumer demand for premium animated content at an all-time high, DreamWorks Animation looked to Lenovo’s Intelligent Devices Group to find innovative workstation solutions that could keep up with its ever-scaling ambitions, increasingly complex workflows and faster production timelines. Designed for high productivity, Lenovo workstations are engineered for power, performance and industry-leading reliability that allow artists to bring their creative ideas to life.
“At DreamWorks, the ability to operate our workflows at the speed of our creative thought process is critical in capturing those instant moments of expression that shape the unforgettable experiences our animators and creative professionals develop. Workstations need to exceed the demands of our artists’ relentless imaginations. Hardware needs to be an enabler; harnessing performance and speed to meet their expectations,” said Bill Ballew, Chief Technology Officer at DreamWorks. “We had the opportunity to test Lenovo’s ThinkStation P620 workstation and realized it’s a game changer for our workflows. Built on the AMD Ryzen™ Threadripper™ PRO architecture, the ThinkStation P620 drives new and improved performance for multi-threaded application environments that our team can take full advantage of.”
From 3D modeling, rigging, surfacing, and simulations to high performance animation and creating hyper-photorealistic renderings, DreamWorks Animation specialists, artists and engineers alike leverage high performance compute capabilities. By relying on the flexibility and future-proofed platforms that Lenovo’s workstations deliver, the DreamWorks’ team can focus on their creative ambitions knowing they are equipped with the world-class technology necessary to meet those complex workflows - now and in the years ahead. In addition to the Lenovo ThinkStation P620, DreamWorks Animation will also be able to take advantage of Lenovo’s most advanced dual processor workstation, the ThinkStation P920. Built with the latest generation of Intel® Xeon® processors, the workstation’s extreme performance will help DreamWorks accelerate their most challenging workflows in a production studio environment.
“We’re excited to expand our partnership with DreamWorks Animation and equip them with workstations that help accelerate their increasingly demanding workflows,” said Rob Herman, Vice President of Lenovo’s Workstation and Client AI Business Unit. “Our workstation collaboration further exemplifies Lenovo’s ability to holistically support our customers with the most advanced technology solutions available, allowing them to innovate faster and transform their respective industries.”
To learn more about how DreamWorks Animation is strengthening its partnership with Lenovo to bring about the next evolution of production, visit: https://techtoday.lenovo.com/us/en/workstations
About Lenovo
Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub .
LENOVO, THINKSTATION and THINKPAD are trademarks of Lenovo. AMD and RYZEN™ are trademarks of Advanced Micro Devices, Inc. Intel, Intel Core and vPro are trademarks of Intel Corporation or its subsidiaries in the U.S. and/or other countries. ©2021, Lenovo Group Limited.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005429/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom